Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma, Synovial 1Sarcoma 1Rhabdomyosarcoma 1Lung Neoplasms 1Liposarcoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1Hemangiopericytoma, Malignant 1Fibrosarcoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Doxorubicin 5Dacarbazine 5Trabectedin 3belinostat 2PTC596 2toripalimab 1soblidotin 1rucaparib 1ridaforolimus 1reolysin 1pembrolizumab 1pazopanib 1olaratumab 1futibatinib 1cixutumumab 1cemiplimab 1anlotinib 1Tablets 1TTI-621 1Rosuvastatin Calcium 1PM 01183 1Midazolam 1Injections 1Imatinib Mesylate 1Ifosfamide 1Fluorouracil 1Erlotinib Hydrochloride 1Docetaxel 1Digoxin 1Dexamethasone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Leiomyosarcoma × soblidotin × Clear all
NCT00064220 2012-05-16

Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma

Daiichi Sankyo

Phase 2 Completed
Sarcoma

Hemangiopericytoma, Malignant, Fibrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Synovial, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡